| dc.description.abstract | Due to the impact of living conditions, the incidence of cancer is increasing day
by day. In recent years, every year Vietnam discovers a lot of new cancer patients
such as lung cancer, breast cancer and leukemia, … CD 19 is thought to be a promising
target for immunotherapies focused on B-cell malignancies. In the flow cytometry
technique to identify B cells, in addition to the FACS device, the CD19 marker specific
monoclonal antibody is an indispensable material. All anti-human CD19 antibodies
used in diagnosis and research are imported biological products with high cost and
need more time to deliver. With the high demand for current and future use of antihuman CD19 monoclonal antibodies in disease diagnosis and research. We want to
create a low-cost monoclonal antibody system for future studies based on commercial
antibody imitation and using pFUSE and pOptiVEC vectors for expression.
In this study, based on the published sequence on reliable data, we selected
and mimic to generate recombinant plasmid encoded anti-human CD19 monoclonal
antibody, transformation into E Coli, screening of E. coli lines carrying target gene
and expressing it from CHO-DG44 cells. The pFUSE vector containing the antibiotic
resistance gene Zeocin or Blasticidine is used with the expectation that the
recombinant plasmid will have a higher expression level and more specificity. The
pOptiVEC vector carrying the gene encoding the DHFR protein, the recombinant
plasmid will be able to simultaneously express DHFR – protein required to growth
CHO cells on nucleoside deficient medium MEM (-) and monoclonal antibodies.
Since then, the combination of two recombinant plasmids with the hope of
higher expression levels in both intracellular and extracellular. And we may be able
to identify the right ratio of light chain and heavy chain plasmids to co-transform into
CHO-DG44 cells in order to generate extracellular anti-human CD19 monoclonal
antibody. | en_US |
